Literature DB >> 22894618

Mechanisms of β-lactam resistance among Pseudomonas aeruginosa.

Daniel J Wolter1, Philip D Lister.   

Abstract

Treatment of serious P. aeruginosa infections becomes more challenging with each passing year. As this pathogen acquires more transferrable resistance mechanisms and continues to rapidly adapt and emerge resistant during the course of antimicrobial therapy, we face the growing threat of pan-resistance. This review has focused on those mechanisms that directly impact the future of β-lactam antibiotics, including the production of β-lactamases, porin-mediated resistance, and/or the overexpression of RND efflux pumps. With the pipeline of new anti-pseudomonal agents diminishing, it is essential that novel therapeutic strategies be explored. These include targeting biofilm formation and maintenance, virulence factors, and resistance mechanisms. Furthermore, we must continue to search for effective antibacterial combinations to not only prevent further emergence of resistance but also treat resistant strains already in the environment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22894618

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  25 in total

1.  High-throughput, Highly Sensitive Analyses of Bacterial Morphogenesis Using Ultra Performance Liquid Chromatography.

Authors:  Samantha M Desmarais; Carolina Tropini; Amanda Miguel; Felipe Cava; Russell D Monds; Miguel A de Pedro; Kerwyn Casey Huang
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

2.  Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.

Authors:  Scott R Evans; Thuy Tien T Tran; Andrea M Hujer; Carol B Hill; Kristine M Hujer; Jose R Mediavilla; Claudia Manca; T Nicholas Domitrovic; Federico Perez; Michael Farmer; Kelsey M Pitzer; Brigid M Wilson; Barry N Kreiswirth; Robin Patel; Michael R Jacobs; Liang Chen; Vance G Fowler; Henry F Chambers; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China.

Authors:  Y Chen; M Sun; M Wang; Y Lu; Z Yan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-06       Impact factor: 3.267

4.  Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.

Authors:  Diansy Zincke; Deepak Balasubramanian; Lynn L Silver; Kalai Mathee
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

Review 5.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

6.  Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Krisztina M Papp-Wallace; Elise T Zeiser; Scott A Becka; Steven Park; Brigid M Wilson; Marisa L Winkler; Roshan D'Souza; Indresh Singh; Granger Sutton; Derrick E Fouts; Liang Chen; Barry N Kreiswirth; Evelyn J Ellis-Grosse; George L Drusano; David S Perlin; Robert A Bonomo
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

7.  Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.

Authors:  Charles-Edouard Luyt; Alexandra Aubry; Qin Lu; Maïté Micaelo; Nicolas Bréchot; Florence Brossier; Hélène Brisson; Jean-Jacques Rouby; Jean-Louis Trouillet; Alain Combes; Vincent Jarlier; Jean Chastre
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

8.  Broad-spectrum resistance of Pseudomonas aeruginosa from shellfish: infrequent acquisition of novel resistance mechanisms.

Authors:  Ana Maravić; Ivica Šamanić; Matilda Šprung; Željana Fredotović; Nada Ilić; Josipa Dragičević; Jasna Puizina
Journal:  Environ Monit Assess       Date:  2018-01-15       Impact factor: 2.513

Review 9.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

10.  New Sequence Type ST3449 in Multidrug-Resistant Pseudomonas aeruginosa Isolates from a Cystic Fibrosis Patient.

Authors:  Catalina Díaz-Ríos; Marta Hernández; David Abad; Laura Álvarez-Montes; Athanasia Varsaki; David Iturbe; Jorge Calvo; Alain A Ocampo-Sosa
Journal:  Antibiotics (Basel)       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.